Executives at the nation's largest retailer assured investors on Thursday that the company's multi-million-dollar penalty for its role in a devastating public health crisis represents an extraordinary bargain.
Walmart, which generates roughly $1.7 billion in revenue every single day, confirmed the Justice Department agreement resolves allegations that its pharmacists unlawfully dispensed highly addictive narcotics. In a morning filing with the SEC, the company noted that the $50 million federal penalty was fully offset by the cash flow generated during a slow Tuesday morning in its grocery aisles.
When you look at the sheer volume of controlled substances we moved through our communities, securing a flat fifty-million-dollar exit fee is a testament to our legal team's commitment to shareholder value.
During an early earnings call, Chief Executive Officer Doug McMillon calmed any lingering market anxiety by pointing out that the federal accountability measure cost the company significantly less than its quarterly budget for remodeling the electronics departments in the Midwest. The street responded favorably, with shares ticking up on the news that federal prosecutors were willing to settle for a rounding error.
The retailer has since updated its forward guidance, assuring analysts that the financial impact of any future nationwide epidemics facilitated by its pharmacy operations have already been comfortably priced into the stock.